Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
Gıancarlo Comı(Vita-Salute San Raffaele University), Ludwig Kappos(Novartis (Switzerland)), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), Nicola De Stefano(University of Siena), Margaretha Stam Moraga(Merck Serono (Switzerland)), Frederik Barkhof(Netherlands Institute for Neuroscience), Florence Casset‐Semanaz(Merck Serono (Switzerland)), Mark S. Freedman, Chris H. Polman(Vrije Universiteit Amsterdam), Bryan T. Hennessy(Royal College of Surgeons in Ireland), Sanda Rocak(Merck Serono (Switzerland)), Bettina Stubinski(Merck Serono S.A. (Switzerland))
Cited by 214
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k